Telix Completes Enrollment of 105 Patients in Japan Phase-3 Study of Illuccix for Prostate Cancer Imaging

On 17 July 2026, Telix Pharmaceuticals Limited announced that it has finished enrolling 105 Japanese patients in its Pha...

Read story →